HIV T-cell therapy - Benitec/City of Hope

Drug Profile

HIV T-cell therapy - Benitec/City of Hope

Alternative Names: Lentivirus-transduced T-cell immunotherapy; pHIV7-shI-TAR-CCR5RZ treated CD4 cells

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Benitec Biopharma; City of Hope National Medical Center
  • Class Cell therapies; RNA; Small interfering RNA
  • Mechanism of Action Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-0 development in HIV-infections in USA (IV, Infusion)
  • 09 Feb 2011 Development is ongoing in USA
  • 13 Nov 2009 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top